TORONTO, ONTARIO--(Marketwired - April 10, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) is pleased to announce that it has today filed a prospectus supplement (the "Prospectus") to the Company's short form base shelf prospectus dated October 15, 2012, regarding its previously announced public offering of units of the Company ("Units"). Each Unit consists of one common share ("Share") of the Company and one Share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to acquire one Share at a price of $2.75 for a period of 36 months following the Closing Date (as defined below).
Dundee Securities Ltd. (the "Agent") has agreed to sell, on a best efforts agency basis and, pursuant to the terms and conditions of an agency agreement dated April 10, 2014 between the Company and the Agent (the "Agency Agreement"), 10,611,469 Units at a price of $2.10 per Unit (the "Offering") for total gross proceeds of $22,284,085. The Agent has been granted the option to offer for sale up to an additional 15% of the Units issued under the Offering, exercisable in whole or in part on the Closing Date or at any time up to 30 days following the Closing Date. BayFront Capital Partners Ltd. is acting as a selling group member in connection with the Offering.
The Offering is scheduled to close on or about April 23, 2014 (the "Closing Date"). The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals.
The Securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any jur
Two days ago that would have come in really handy. Two days too late. Worthless paper. Dilution always is a sell sign. Could have caught the top and bought lower. I suppose the management was shorting the American exchanges as they are not registered here and can do anything they want to. Knowing a short covering was going on and then dilution, they could have covered at the open and made a fortune. No wonder they have diluted the shares twice in two months.
Yet the stock price is up over 500% in the last 5 months. The company was smart and took the opportunity now for it's final financing vs waiting another 12 months which would have suppressed its PPS until then. News is due out May 21st, which is a highly anticipated date for the medical community and all longs. They have all they need now to bring SPORT to commercialization. Get in before May 21st leg up.